Molecular Alterations Associated with Osteosarcoma Development
暂无分享,去创建一个
F. Verrecchia | D. Heymann | K. Mori | F. Redini | K. Ando | B. Marc
[1] D. Heymann,et al. Targeted therapies for bone sarcomas. , 2013, BoneKEy reports.
[2] Sun Mi Park,et al. Erratum: CD95 promotes tumour growth (Nature (2010) 465 (492-496) DOI: 10.1038/nature09075) , 2012 .
[3] B. Qian,et al. Increased expression of insulin‐like growth factor‐1 receptor is correlated with tumor metastasis and prognosis in patients with osteosarcoma , 2012, Journal of surgical oncology.
[4] D. Heymann,et al. Bone sarcomas: pathogenesis and new therapeutic approaches , 2011 .
[5] Ping Chen,et al. Relationships between levels of CXCR4 and VEGF and blood-borne metastasis and survival in patients with osteosarcoma , 2011, Medical oncology.
[6] Quan Tian,et al. Antitumor activity of natural compounds, curcumin and PKF118-310, as Wnt/β-catenin antagonists against human osteosarcoma cells , 2010, Investigational New Drugs.
[7] G. Moriceau,et al. Therapeutic approach of primary bone tumours by bisphosphonates. , 2010, Current pharmaceutical design.
[8] P. Houghton,et al. Fully Human Monoclonal Antibody Targeting IGF-1 R , Is Effective Alone and in Combination With Rapamycin in Inhibiting Growth of Osteosarcoma Xenografts , 2010 .
[9] A. Chambers,et al. Extracellular matrix: a gatekeeper in the transition from dormancy to metastatic growth. , 2010, European journal of cancer.
[10] Bin Wang,et al. Lentivirus-mediated shRNA targeting insulin-like growth factor-1 receptor (IGF-1R) enhances chemosensitivity of osteosarcoma cells in vitro and in vivo , 2010, Molecular and Cellular Biochemistry.
[11] X. Zi,et al. Wnt Inhibitory Factor 1 Decreases Tumorigenesis and Metastasis in Osteosarcoma , 2010, Molecular Cancer Therapeutics.
[12] G. Camussi,et al. Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways , 2009, Molecular Cancer.
[13] G. Camussi,et al. Abstract C213: Sorafenib blocks tumor growth, angiogenesis, and metastatic potential in preclinical models of osteosarcoma through the inhibition of ERK1/2, MCL‐1, and ezrin pathways , 2009 .
[14] Juan Tang,et al. Silencing of calpain expression reduces the metastatic potential of human osteosarcoma cells , 2009, Cell biology international.
[15] E. Kleinerman,et al. Antagonism of chemokine receptor CXCR3 inhibits osteosarcoma metastasis to lungs , 2009, International journal of cancer.
[16] D. Hughes. How the NOTCH pathway contributes to the ability of osteosarcoma cells to metastasize. , 2009, Cancer treatment and research.
[17] Mimi Y. Kim,et al. Correlation between clinical outcome and growth factor pathway expression in osteogenic sarcoma , 2009, Cancer.
[18] E. Haura,et al. Src kinases as therapeutic targets for cancer , 2009, Nature Reviews Clinical Oncology.
[19] Chun-Yin Huang,et al. Stromal cell‐derived factor‐1/CXCR4 enhanced motility of human osteosarcoma cells involves MEK1/2, ERK and NF‐κB‐dependent pathways , 2009, Journal of cellular physiology.
[20] H. Okamura,et al. Immunotherapy with Interleukin-18 in Combination with Preoperative Chemotherapy with Ifosfamide Effectively Inhibits Postoperative Progression of Pulmonary Metastases in a Mouse Osteosarcoma Model , 2009, Tumor Biology.
[21] D. Heymann,et al. Mechanisms of bone repair and regeneration. , 2009, Trends in molecular medicine.
[22] S. Jung,et al. Risedronate inhibits human osteosarcoma cell invasion , 2009, Journal of experimental & clinical cancer research : CR.
[23] H. Seewald,et al. Insulin-like growth factor I correlations to changes of the hormonal status in puberty and age. , 2009, Experimental and clinical endocrinology.
[24] H. Sasaki,et al. Inhibition of Notch pathway prevents osteosarcoma growth by cell cycle regulation , 2009, British Journal of Cancer.
[25] R. Iozzo,et al. Basement membrane proteoglycans: Modulators Par Excellence of cancer growth and angiogenesis , 2009, Molecules and cells.
[26] R. Gorlick,et al. Inhibition of Src Phosphorylation Alters Metastatic Potential of Osteosarcoma In vitro but not In vivo , 2009, Clinical Cancer Research.
[27] L. Helman,et al. Beta4 integrin promotes osteosarcoma metastasis and interacts with ezrin , 2009, Oncogene.
[28] Raphael Kopan,et al. The Canonical Notch Signaling Pathway: Unfolding the Activation Mechanism , 2009, Cell.
[29] L. Donehower,et al. Notch signaling contributes to the pathogenesis of human osteosarcomas. , 2009, Human molecular genetics.
[30] A. Strasser,et al. The many roles of FAS receptor signaling in the immune system. , 2009, Immunity.
[31] Zhaoxia Wang,et al. Lentivirus-mediated RNAi knockdown of insulin-like growth factor-1 receptor inhibits growth, reduces invasion, and enhances radiosensitivity in human osteosarcoma cells , 2009, Molecular and Cellular Biochemistry.
[32] S. Hewitt,et al. The actin-cytoskeleton linker protein ezrin is regulated during osteosarcoma metastasis by PKC , 2009, Oncogene.
[33] M. Padrines,et al. Proteases and bone remodelling. , 2009, Cytokine & growth factor reviews.
[34] Paola Chiarugi,et al. Anoikis: a necessary death program for anchorage-dependent cells. , 2008, Biochemical pharmacology.
[35] S. Indraccolo,et al. Cellular interactions in the vascular niche: implications in the regulation of tumor dormancy , 2008, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[36] R. Vessella,et al. Cancer micrometastasis and tumour dormancy , 2008, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[37] C. Xian,et al. Roles of Wnt signalling in bone growth, remodelling, skeletal disorders and fracture repair , 2008, Journal of cellular physiology.
[38] S. Keir,et al. Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF‐1 receptor by the pediatric preclinical testing program , 2008, Pediatric blood & cancer.
[39] Yan-wen Yang,et al. Critical Role of Notch Signaling in Osteosarcoma Invasion and Metastasis , 2008, Clinical Cancer Research.
[40] C. Napoli,et al. Deletion of Yin Yang 1 protein in osteosarcoma cells on cell invasion and CXCR4/angiogenesis and metastasis. , 2008, Cancer research.
[41] D. Heymann,et al. Liposomal muramyl tripeptide phosphatidyl ethanolamine: a safe and effective agent against osteosarcoma pulmonary metastases , 2008, Expert review of anticancer therapy.
[42] Lloyd J. Old,et al. Adaptive immunity maintains occult cancer in an equilibrium state , 2007, Nature.
[43] Young-Chae Chang,et al. Disulfiram suppresses invasive ability of osteosarcoma cells via the inhibition of MMP-2 and MMP-9 expression. , 2007, Journal of biochemistry and molecular biology.
[44] J. Aguirre-Ghiso,et al. Models, mechanisms and clinical evidence for cancer dormancy , 2007, Nature Reviews Cancer.
[45] E. Kleinerman,et al. Fas-Negative Osteosarcoma Tumor Cells Are Selected during Metastasis to the Lungs: The Role of the Fas Pathway in the Metastatic Process of Osteosarcoma , 2007, Molecular Cancer Research.
[46] Andrea Giustina,et al. Mechanisms of anabolic therapies for osteoporosis. , 2007, The New England journal of medicine.
[47] M. Colombo,et al. Caveolin-1 reduces osteosarcoma metastases by inhibiting c-Src activity and met signaling. , 2007, Cancer research.
[48] R. Holcombe,et al. Blocking Wnt/LRP5 signaling by a soluble receptor modulates the epithelial to mesenchymal transition and suppresses met and metalloproteinases in osteosarcoma Saos‐2 cells , 2007, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.
[49] R. Baron,et al. Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. , 2007, Endocrinology.
[50] S. Eccles,et al. Metastasis: recent discoveries and novel treatment strategies , 2007, The Lancet.
[51] M. Peter,et al. The CD95 Receptor: Apoptosis Revisited , 2007, Cell.
[52] R. Jove,et al. Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival. , 2007, Cancer research.
[53] David M. Thomas,et al. Molecular pathogenesis of osteosarcoma. , 2007, DNA and cell biology.
[54] R. Kaplan,et al. Bone marrow cells in the ‘pre-metastatic niche’: within bone and beyond , 2007, Cancer and Metastasis Reviews.
[55] G. Bacci,et al. Primary bone osteosarcoma in the pediatric age: state of the art. , 2006, Cancer treatment reviews.
[56] G. Inghirami,et al. β4 Integrin Amplifies ErbB2 Signaling to Promote Mammary Tumorigenesis , 2006, Cell.
[57] P. Steeg. Tumor metastasis: mechanistic insights and clinical challenges , 2006, Nature Medicine.
[58] Q. Tao,et al. Inactivation of Wnt inhibitory factor-1 (WIF1) expression by epigenetic silencing is a common event in breast cancer. , 2006, Carcinogenesis.
[59] B. McIntyre,et al. PI3-K/Akt-mediated anoikis resistance of human osteosarcoma cells requires Src activation. , 2006, European journal of cancer.
[60] F. Bertoni,et al. Influence of local recurrence on survival in patients with extremity osteosarcoma treated with neoadjuvant chemotherapy , 2006, Cancer.
[61] Susan O'Brien,et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. , 2006, The New England journal of medicine.
[62] A. Puisieux,et al. Metastasis: a question of life or death , 2006, Nature Reviews Cancer.
[63] H. Körner,et al. Trypsin in colorectal cancer: molecular biological mechanisms of proliferation, invasion, and metastasis , 2006, The Journal of pathology.
[64] E. Kleinerman,et al. Intranasal interleukin‐12 gene therapy enhanced the activity of ifosfamide against osteosarcoma lung metastases , 2006, Cancer.
[65] Cheng-Ta Yang,et al. Wnt signaling activation and WIF-1 silencing in nasopharyngeal cancer cell lines. , 2006, Biochemical and biophysical research communications.
[66] David Zurakowski,et al. A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. , 2006, Journal of the National Cancer Institute.
[67] H. Okamura,et al. Effect of interleukin-18 on metastasis of mouse osteosarcoma cells , 2006, Cancer Immunology, Immunotherapy.
[68] M. Tatematsu,et al. Chemical genomic screening for methylation‐silenced genes in gastric cancer cell lines using 5‐aza‐2′‐deoxycytidine treatment and oligonucleotide microarray , 2006, Cancer science.
[69] R. Stan,et al. Structure of caveolae. , 2005, Biochimica et biophysica acta.
[70] E. Kleinerman,et al. Interleukin-12 Up-Regulates Fas Expression in Human Osteosarcoma and Ewing's Sarcoma Cells by Enhancing Its Promoter Activity , 2005, Molecular Cancer Research.
[71] E. Kleinerman,et al. Fas Expression in Lung Metastasis From Osteosarcoma Patients , 2005, Journal of pediatric hematology/oncology.
[72] Moshe Talpaz,et al. Dasatinib (BMS-354825) Tyrosine Kinase Inhibitor Suppresses Invasion and Induces Cell Cycle Arrest and Apoptosis of Head and Neck Squamous Cell Carcinoma and Non–Small Cell Lung Cancer Cells , 2005, Clinical Cancer Research.
[73] Wen-Hui Weng,et al. Prognostic Impact of Immunohistochemical Expression of Ezrin in Highly Malignant Soft Tissue Sarcomas , 2005, Clinical Cancer Research.
[74] O. Fodstad,et al. Matrix metalloproteinases participate in osteosarcoma invasion. , 2005, The Journal of surgical research.
[75] Hans Clevers,et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. , 2005, Developmental cell.
[76] A. Vaheri,et al. Ezrin in primary cutaneous melanoma , 2005, Modern Pathology.
[77] A. Huvos,et al. Messenger RNA Expression Levels of CXCR4 Correlate with Metastatic Behavior and Outcome in Patients with Osteosarcoma , 2005, Clinical Cancer Research.
[78] E. Kleinerman,et al. Increased Fas Expression Reduces the Metastatic Potential of Human Osteosarcoma Cells , 2004, Clinical Cancer Research.
[79] F. Giancotti,et al. Integrin β4 signaling promotes tumor angiogenesis , 2004 .
[80] Michael D Schaller,et al. The interplay between Src and integrins in normal and tumor biology , 2004, Oncogene.
[81] D. Auclair,et al. BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.
[82] E. Kohn,et al. Anoikis: Cancer and the homeless cell , 2004, Nature.
[83] F. Watt,et al. Switch from αvβ5 to αvβ6 integrin expression protects squamous cell carcinomas from anoikis , 2004, The Journal of cell biology.
[84] Biao He,et al. Wnt Inhibitory Factor-1 Is Silenced by Promoter Hypermethylation in Human Lung Cancer , 2004, Cancer Research.
[85] M. Kreuter,et al. Prognostic relevance of increased angiogenesis in osteosarcoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[86] D. Heymann,et al. Bisphosphonates: new therapeutic agents for the treatment of bone tumors. , 2004, Trends in molecular medicine.
[87] Ruud H. Brakenhoff,et al. Dissecting the metastatic cascade , 2004, Nature Reviews Cancer.
[88] K. Hunter. Ezrin, a key component in tumor metastasis. , 2004, Trends in molecular medicine.
[89] S. Kumta,et al. Alendronate regulates cell invasion and MMP‐2 secretion in human osteosarcoma cell lines , 2004, Pediatric blood & cancer.
[90] J. Healey,et al. Dickkopf 3 inhibits invasion and motility of Saos-2 osteosarcoma cells by modulating the Wnt-beta-catenin pathway. , 2004, Cancer research.
[91] T. Meshel,et al. The expression of the chemokine receptor CXCR3 and its ligand, CXCL10, in human breast adenocarcinoma cell lines. , 2004, Immunology letters.
[92] A. Huvos,et al. Expression of LDL receptor‐related protein 5 (LRP5) as a novel marker for disease progression in high‐grade osteosarcoma , 2004, International journal of cancer.
[93] Stephen M Hewitt,et al. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis , 2004, Nature Medicine.
[94] D. Mikulic,et al. TUMOR ANGIOGENESIS AND OUTCOME IN OSTEOSARCOMA , 2004, Pediatric hematology and oncology.
[95] Jason L. Townson,et al. Ineffectiveness of Doxorubicin Treatment on Solitary Dormant Mammary Carcinoma Cells or Late-developing Metastases , 2003, Breast Cancer Research and Treatment.
[96] P. Meltzer,et al. Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[97] B. McIntyre,et al. Acquisition of anoikis resistance in human osteosarcoma cells. , 2003, European journal of cancer.
[98] H. Clevers,et al. Survivin and molecular pathogenesis of colorectal cancer , 2003, The Lancet.
[99] Yoshiaki Kawano,et al. Secreted antagonists of the Wnt signalling pathway , 2003, Journal of Cell Science.
[100] T. Salo,et al. Inhibition of matrix metalloproteinase-14 in osteosarcoma cells by clodronate. , 2003, The Journal of surgical research.
[101] W. Schmiegel,et al. Adeno-associated virus mediated gene transfer of endostatin inhibits angiogenesis and tumor growth in vivo , 2003 .
[102] Larry Kedes,et al. HES and HERP families: Multiple effectors of the notch signaling pathway , 2003, Journal of cellular physiology.
[103] Andreas Friedl,et al. Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[104] F. Nestle,et al. Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells. , 2002, Cancer research.
[105] A. Montag,et al. Cytoplasmic and/or nuclear accumulation of the β‐catenin protein is a frequent event in human osteosarcoma , 2002, International journal of cancer.
[106] Gordon Stamp,et al. Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. , 2002, Cancer research.
[107] L. Ellis,et al. Phase I study of recombinant human endostatin in patients with advanced solid tumors. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[108] Donald W Kufe,et al. Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[109] S. Steinberg,et al. Treatment of Metastatic Osteosarcoma With the Somatostatin Analog OncoLar: Significant Reduction of Insulin-Like Growth Factor-1 Serum Levels , 2002, Journal of pediatric hematology/oncology.
[110] E. Kleinerman,et al. Fas expression inversely correlates with metastatic potential in osteosarcoma cells. , 2002, Oncology reports.
[111] S. Hewitt,et al. A randomized controlled trial of octreotide pamoate long-acting release and carboplatin versus carboplatin alone in dogs with naturally occurring osteosarcoma: evaluation of insulin-like growth factor suppression and chemotherapy. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[112] N. Muzyczka,et al. Adeno-associated virus–mediated gene transfer of endostatin inhibits angiogenesis and tumor growth in vivo , 2002, Cancer Gene Therapy.
[113] Yasuhito Kato,et al. Relationship between expression of matrix metalloproteinase-2 and matrix metalloproteinase-9 and invasion ability of cervical cancer cells. , 2002, Oncology reports.
[114] P. Krammer,et al. Tumor Immunology , 2018, Medical Immunology.
[115] N. Longo,et al. Expression of Functional Chemokine Receptors CXCR3 and CXCR4 on Human Melanoma Cells* , 2001, The Journal of Biological Chemistry.
[116] L. Trusolino,et al. A Signaling Adapter Function for α6β4 Integrin in the Control of HGF-Dependent Invasive Growth , 2001, Cell.
[117] G. Wilding,et al. Tissue examination to monitor antiangiogenic therapy: a phase I clinical trial with endostatin. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[118] R. D'Amato,et al. Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. , 2001, Cancer research.
[119] P. Murphy,et al. Chemokines and the molecular basis of cancer metastasis. , 2001, The New England journal of medicine.
[120] A. Feldman,et al. Effect of retroviral endostatin gene transfer on subcutaneous and intraperitoneal growth of murine tumors. , 2001, Journal of the National Cancer Institute.
[121] P. Leavey,et al. Lack of Prognostic Significance of Intratumoral Angiogenesis in Nonmetastatic Osteosarcoma , 2001, Journal of pediatric hematology/oncology.
[122] Y. Soini,et al. Expression of MMP2, MMP9, MT1‐MMP, TIMP1, and TIMP2 mRNA in valvular lesions of the heart , 2001, The Journal of pathology.
[123] E. Kleinerman,et al. Interleukin (IL)-12 and IL-12 gene transfer up-regulate Fas expression in human osteosarcoma and breast cancer cells. , 2001, Cancer research.
[124] P. Meltzer,et al. Metastasis-associated differences in gene expression in a murine model of osteosarcoma. , 2001, Cancer research.
[125] J. Schölmerich,et al. Apoptotic signaling during initiation of detachment-induced apoptosis ("anoikis") of primary human intestinal epithelial cells. , 2001, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[126] T. Mcclanahan,et al. Involvement of chemokine receptors in breast cancer metastasis , 2001, Nature.
[127] T. Danciu,et al. Caveolin‐Enriched Membrane Signaling Complexes in Human and Murine Osteoblasts , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[128] Shigeyoshi Itohara,et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis , 2000, Nature Cell Biology.
[129] G. Murphy,et al. Functional Significance of MMP-9 in Tumor Necrosis Factor-Induced Proliferation and Branching Morphogenesis of Mammary Epithelial Cells. , 2000, Endocrinology.
[130] P. Polakis. Wnt signaling and cancer. , 2000, Genes & development.
[131] V. Sukhatme,et al. Synergy between angiostatin and endostatin: inhibition of ovarian cancer growth. , 2000, Cancer research.
[132] J. Gołąb. Interleukin 18--interferon gamma inducing factor--a novel player in tumour immunotherapy? , 2000, Cytokine.
[133] W. Fridman,et al. Interleukin-18: biological properties and clinical implications. , 2000, European cytokine network.
[134] W. Kiess,et al. Insulin-like growth factor-I inhibits the progression of human U-2 OS osteosarcoma cells towards programmed cell death through interaction with the IGF-I receptor. , 2000, Cellular and molecular biology.
[135] F. Higashino,et al. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[136] D. Dorfman,et al. The chemokine receptor CXCR3 is expressed in a subset of B-cell lymphomas and is a marker of B-cell chronic lymphocytic leukemia. , 2000, Blood.
[137] J. Wigginton,et al. IFN-γ-Dependent Delay of In Vivo Tumor Progression by Fas Overexpression on Murine Renal Cancer Cells1 2 , 2000, The Journal of Immunology.
[138] T. Pawlik,et al. Mouse endostatin inhibits the formation of lung and liver metastases. , 1999, Cancer research.
[139] M. Kurimoto,et al. Interleukin‐18 acts as an angiogenesis and tumor suppressor , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[140] 河合 伸泰. Serum Free Insulin-Like Growth Factor I(IGF-I),Total IGF-I,and IGF- Binding Protein-3 Concentrations in Normal Children and Children with Growth Hormone Deficiency , 1999 .
[141] Y. Oshika,et al. Cell-retained isoforms of vascular endothelial growth factor (VEGF) are correlated with poor prognosis in osteosarcoma. , 1999, European journal of cancer.
[142] A. Gautreau,et al. Ezrin, a plasma membrane-microfilament linker, signals cell survival through the phosphatidylinositol 3-kinase/Akt pathway. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[143] V. Sukhatme,et al. Cloning, Expression, andin VitroActivity of Human Endostatin , 1999 .
[144] Paul Polakis,et al. The metalloproteinase matrilysin is a target of β-catenin transactivation in intestinal tumors , 1999, Oncogene.
[145] P. Mangeat,et al. ERM proteins in cell adhesion and membrane dynamics. , 1999, Trends in cell biology.
[146] S. Artavanis-Tsakonas,et al. Notch signaling: cell fate control and signal integration in development. , 1999, Science.
[147] Frank McCormick,et al. β-Catenin regulates expression of cyclin D1 in colon carcinoma cells , 1999, Nature.
[148] M. Gondo,et al. Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene , 1999, Nature Biotechnology.
[149] J. Nathans,et al. A new secreted protein that binds to Wnt proteins and inhibits their activites , 1999, Nature.
[150] Yusuke Nakamura,et al. Frequent β‐Catenin Abnormalities in Bone and Soft‐tissue Tumors , 1999, Japanese journal of cancer research : Gann.
[151] L. Owen-Schaub,et al. Fas and Fas Ligand Interactions Suppress Melanoma Lung Metastasis , 1998, The Journal of experimental medicine.
[152] J. Wigginton,et al. Molecular mechanisms of immune-mediated lysis of murine renal cancer: differential contributions of perforin-dependent versus Fas-mediated pathways in lysis by NK and T cells. , 1998, Journal of immunology.
[153] A. Sparks,et al. Identification of c-MYC as a target of the APC pathway. , 1998, Science.
[154] D. Campanacci,et al. Expression of transforming growth factor β isoforms in osteosarcoma variants: association of tgfβ1 with high‐grade osteosarcomas , 1998 .
[155] J. Folkman,et al. Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases. , 1998, The Journal of clinical investigation.
[156] Ø. Bruland,et al. On the current management of osteosarcoma. A critical evaluation and a proposal for a modified treatment strategy. , 1997, European journal of cancer.
[157] T. Tanimoto,et al. Interleukin 18 enhances Fas ligand expression and induces apoptosis in Fas-expressing human myelomonocytic KG-1 cells. , 1997, Anticancer research.
[158] William Arbuthnot Sir Lane,et al. Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth , 1997, Cell.
[159] T. Sasaki,et al. Regulation mechanism of ERM (ezrin/radixin/moesin) protein/plasma membrane association: possible involvement of phosphatidylinositol turnover and Rho-dependent signaling pathway , 1996, The Journal of cell biology.
[160] M. Maa,et al. Potentiation of epidermal growth factor receptor-mediated oncogenesis by c-Src: implications for the etiology of multiple human cancers. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[161] Z. Werb,et al. Suppression of ICE and apoptosis in mammary epithelial cells by extracellular matrix , 1995, Science.
[162] Lars Holmgren,et al. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma , 1994, Cell.
[163] S. Hirschfeld,et al. Human osteosarcoma cell lines are dependent on insulin-like growth factor I for in vitro growth. , 1994, Cancer research.
[164] C. Heldin,et al. Identification of two juxtamembrane autophosphorylation sites in the PDGF beta‐receptor; involvement in the interaction with Src family tyrosine kinases. , 1993, The EMBO journal.
[165] R. Bell,et al. Inhibition of metastatic behavior of murine osteosarcoma by hypophysectomy. , 1992, Journal of the National Cancer Institute.
[166] J. Folkman,et al. The role of angiogenesis in tumor growth. , 1992, Seminars in cancer biology.
[167] Richard G. W. Anderson,et al. Caveolin, a protein component of caveolae membrane coats , 1992, Cell.
[168] D. Goeddel,et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. , 1989, Science.
[169] H. Inoue,et al. Amplification of Both c‐myc and c‐raf‐1 Oncogenes in a Human Osteosarcoma , 1989, Japanese journal of cancer research : Gann.
[170] W. Thompson,et al. Tumours acquire their vasculature by vessel incorporation, not vessel ingrowth , 1987, The Journal of pathology.
[171] M. Mison,et al. Osteosarcoma , 1985, The Lancet.
[172] H. Dvorak,et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. , 1983, Science.
[173] G. Rosen,et al. Preoperative chemotherapy for osteogenic sarcoma: Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy , 1982, Cancer.
[174] W. Enneking,et al. A System for the Surgical Staging of Musculoskeletal Sarcoma , 1980, Clinical orthopaedics and related research.
[175] L. Dehner,et al. Metastatic osteosarcoma to lung. A clinicopathologic study of surgical biopsies and resections , 1977 .
[176] C. H. Price,et al. The metastatic patterns of osteosarcoma. , 1975, British Journal of Cancer.
[177] D. Dorfman,et al. lymphomas and is a marker of B-cell chronic lymphocytic leukemia The chemokine receptor CXCR3 is expressed in a subset of B-cell , 2013 .
[178] Sun-Mi Park,et al. CD95 promotes tumour growth , 2011, Nature.
[179] D. Heymann. Bone Cancer Progression and Therapeutic Approaches , 2009 .
[180] R. Baron,et al. Minireview: Targeting the Wnt/-Catenin Pathway to Regulate Bone Formation in the Adult Skeleton , 2007 .
[181] C. Bokemeyer,et al. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. , 2006, Cancer research.
[182] T. Ishida,et al. Cytoplasmic and/or nuclear staining of beta-catenin is associated with lung metastasis , 2004, Clinical & Experimental Metastasis.
[183] S. Frisch,et al. Anoikis mechanisms. , 2001, Current opinion in cell biology.
[184] S. Ferrari,et al. Pattern of relapse in patients with osteosarcoma of the extremities treated with neoadjuvant chemotherapy. , 2001, European journal of cancer.
[185] A. Al-Mehdi,et al. Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: a new model for metastasis , 2000, Nature Medicine.
[186] J. Hwang,et al. Functional significance of MMP-9 in tumor necrosis factor-induced proliferation and branching morphogenesis of mammary epithelial cells. , 2000, Endocrinology.
[187] V. Sukhatme,et al. Cloning, expression, and in vitro activity of human endostatin. , 1999, Biochemical and biophysical research communications.
[188] S. Kanzaki,et al. Serum free insulin-like growth factor I (IGF-I), total IGF-I, and IGF-binding protein-3 concentrations in normal children and children with growth hormone deficiency. , 1999, The Journal of clinical endocrinology and metabolism.
[189] Lars Holmgren,et al. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression , 1995, Nature Medicine.
[190] Z. Werb,et al. Suppression of ICE and apoptosis in mammary epithelial cells by the extracellular matrix and the cytoskeleton , 1995 .
[191] K. Danø,et al. Plasminogen activators, tissue degradation, and cancer. , 1985, Advances in cancer research.